期刊文献+

9-硝基喜树碱复合磷脂隐形脂质体的制备工艺研究 被引量:1

Study on Preparation of 9-Nitrocamptothecin Stealth Liposomes Composed of DPPC and SPC
下载PDF
导出
摘要 目的考察9-硝基喜树碱(9-nitrocamptothecin,9-NC)复合磷脂隐形脂质体的制备方法与工艺,并进一步比较了经隐形修饰对9-NC复合磷脂脂质体的药剂学性质的影响。方法建立了采用滤膜法测定9-NC脂质体包封率的方法,并以包封率为评价指标,考察了9-NC复合磷脂隐形脂质体的制备方法并优化了制备工艺参数。然后以未经隐形修饰的9-NC复合磷脂脂质体为对照,进一步考察了包封率、粒径、多分散系数、Zeta电位、内酯稳定性等药剂学性质。结果采用薄膜-超声法制备9-NC复合磷脂隐形脂质体包封率高于乙醇注入法,进一步考察得到其优化的工艺参数为复合磷脂摩尔比例HSPC∶SPC=1∶9(摩尔比),成膜时间与压力分别为100min与0.095MPa。隐形修饰对9-NC复合磷脂脂质体的包封率(80%以上)影响不大,同时也不会影响其表面电位,但经隐形修饰后粒径显著减小,内酯稳定性显著增加。结论采用最优方法与工艺制备的9-NC复合磷脂隐形脂质体包封率高,载药效果能够满足体内研究的需要;隐形修饰有利于提高9-NC复合磷脂脂质体的内酯稳定性。 OBJECTIVE To investigate the preparing methods and process of 9-nitrocamptothecin (9-NC) stealth liposomes composed of HSPC and SPC and to compare the pharmaceutical properties between 9-NC liposomes and 9-NC stealth liposomes.METHODS Encapsulation efficiency determination method for 9-NC stealth liposomes was established by ultrafiltration membrane method.The preparation for 9-NC stealth stealth liposomes was carefully studied and the process parameters were optimized.Furthermore,compared with 9-NC liposomes composed of HSPC and SPC without stealth-modified,encapsulation efficiency,particle size,zeta potential and polydispersity lactone stability were investigated.RESULTS The encapsulation efficiency of 9-NC stealth liposomes preparation by film-ultrasonic method was significantly improved,compared to those by ethanol injection method,and the optimized process parameters were HSPC∶ SPC=1∶9.The formation time was 100min and formation pressure was 0.095 Mpa.Though there was on influence on the exception of encapsulation efficiency (80%) and zeta potential,particle size and lactone stability were significantly optimized by modified stealth materials.CONCLUSION Samples prepared by optimized method and process obtained high encapsulation efficiency and met the needs of drug effects in vivo studies; modified stealth materials may have effect in enhancing Lactone stability of 9-NC stealth liposomes composed of HSPC and SPC.
出处 《南京中医药大学学报》 CAS CSCD 北大核心 2014年第2期168-172,共5页 Journal of Nanjing University of Traditional Chinese Medicine
基金 湖北省教育厅科学技术研究计划重点项目(D20114301) 南京中医药大学青年自然科学基金(11XZR12)
关键词 9-硝基喜树碱 隐形脂质体 制备工艺和条件 药剂学性质 9-nitrocamptothecin stealth liposomes preparation technology and condition pharmaceutical properties
  • 相关文献

参考文献6

  • 1Fassberg J, Stella VJ. A kinetic and mechanistic study of the hy- drolysis of camptothecin and some analogues[J]. J Pharm Sci, 1992, 81(7): 676-684.
  • 2Chen J, Ping QN, Guo JX, et al. Effect of phospholipid compo- sition on characterization of liposomes containing 9-nitrocampto- theein[J]. Drug Dev Ind Pharm, 2006, 32(6):719-726.
  • 3Immordino ML, Dosio F, Cattel L'. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential[J]. Int J Nanomedicine, 2006, 1(3): 297-315.
  • 4郭健新,平其能,黄罗生.柔性环孢素纳米脂质体的制备及其变形性[J].中国药科大学学报,1999,30(3):187-191. 被引量:44
  • 5陈军,平其能,郭健新,丁明港.脂质体对9-硝基喜树碱内酯型和羧酸盐型体外平衡的影响[J].中国药科大学学报,2005,36(4):316-320. 被引量:18
  • 6Zhong DF, Li K, Xu JH, et al. Pharmacokinetics of 9-nitro-20 (S)-camptothecin in rats[J]. Acta Pharmacol Sin, 2003, 24(3) :256-262.

二级参考文献14

  • 1周卫,平其能,王丽杰.羟喜树碱脂质体的粒径对组织分布的影响[J].中国药科大学学报,2005,36(2):125-128. 被引量:15
  • 2翁帼英 陈明非.脂质体中卵磷脂的氧化产物与溶血的关系[J].生物化学与生物物理进展,1990,17(1):76-76.
  • 3翁帼英,生物化学与生物物理进展,1990年,17卷,1期,76页
  • 4Wang D P,Drug Dev Ind Pharm,1997年,23卷,1期,99页
  • 5Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability [ J ]. J Med Chem,1994,37(1):40-46.
  • 6Shenderova A, Burke TG, Schwendeman SP. Stabilization of 10-hydroxycamptothecin in poly(lactide-glycolide) microsphere delivery vehicles[J]. Pharm Res, 1997,14(10): 1 406 - 1 414.
  • 7Hung CL, Doniger J, Palini A, et al. 9-Nitrocamptothecin inhibits HIV-1 replication in human periperal blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy[J]. J Med Virol, 2001,64(3) :238 - 244.
  • 8Cao Z, Harris N, Kozielski A, et al. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity,and antitumor activity[J]. J Med Chem, 1998,41( 1 ) :31 - 37.
  • 9Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity [ J ]. J Med Chem, 1989, 32(3) :715 - 720.
  • 10Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues [ J ]. J Pharm Sci,1992,81(7) :676 - 684.

共引文献60

同被引文献10

  • 1陈军,平其能,蔡宝昌.9-硝基喜树碱复合磷脂脂质体的研究[c].中国药学会年会会议论文集,2006:1411-1420.
  • 2BERNACKI R J, PERA P, GAMBACORTA P, et al. In vitro antitumor activity of 9-nitrocamptothecin as a single agent and in combination with other antitumor drugs [J]. Ann N Y Aead Sci, 2000(922): 293-297.
  • 3AMORINO G P, HERCULES S K, MOHR P J, et al. Preclinical evaluation of the orally active camptothecin analog, RFS-2000(9-nitro-20(s)-camptothecin) as a radiation enhancer [J]. Int J Radiat Oneol Biol Phys, 2000, 47(20): 503-509.
  • 4HUNG C L, DONIGER J, PALINI A, et al. 9-Nitrocamptothecin inhibits periperal blood lymphocytes HIV-1 replication in human I-IIV-infection/AIDS therapy [J] 238-244. a potential alternative for J Med Virol, 2001, 64(3):.
  • 5CEH B, W1NTERHALTER M, FREDERIK P M, et al. Stealth liposomes: from theory to product [J]. Adv Drug Deliv Rew, 1997, 24(2/3): 75-87.
  • 6FATTEL L, CERUTI M, DOSIO F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy [J]. Tumori, 2003, 89(3): 237-247.
  • 7HASHIDA H, TAKABAYASHI A, KANAI M, et al. Aminopetidase N is involved in cell motiltiy and angiogenesis: its clinical significance in humanelone cancer [J]. Gastroen- terology, 2002, 122(2): 376-386.
  • 8IKEDMA N, NAKAJIMA Y, TOKUHARA T, et al. Clinical significance of aminopetidase N/CD13 expression in human pancreatic carcinoma [J]. Clin Cancer Res, 2003, 9(4): 1503-1508.
  • 9周虹,黄向阳,杨婷,汪涛,徐丹,文富强.LY294002对人纤维肉瘤HT1080细胞生长的影响及机制研究[J].四川大学学报(医学版),2010,41(1):20-23. 被引量:1
  • 10彭佩,林爱华,陈军,王咏,顾薇,赖小纯.NGR修饰的香豆素-6隐形脂质体的制备及其体外细胞摄取性质[J].中国医院药学杂志,2014,34(6):427-432. 被引量:11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部